Rechallenge therapy and treatment holiday: Different strategies in management of metastatic colorectal cancer

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Tonini, Giuseppe ^a   Imperatori, Marco ^a   Vincenzi, Bruno ^a   Frezza, Anna Maria ^a   Santini, Daniele ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Colorectal cancer; Drug resistance; Intermittent treatment; Rechallenge therapy

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE;

CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG EFFECT; DRUG EFFICACY; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; INDUCTION CHEMOTHERAPY; METASTATIC COLORECTAL CANCER; MORNING DOSAGE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MUTAGENESIS; ONCOGENE K RAS; OVERALL SURVIVAL; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; COLORECTAL NEOPLASMS; DRUG RESISTANCE; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 84887632994     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-92     Document Type: Review

References (50)

1. Increased expression of CD133 and reduced dystroglycan expression are strong predictors of poor outcome in colon cancer patients. Coco C, Zannoni GF, Caredda E, Sioletic S, Boninsegna A, Migaldi M, Rizzo G, Bonetti LR, Genovese G, Stigliano E, Cittadini A, Sgambato A, J Exp Clin Cancer Res 2012 31 71 10.1186/1756-9966-31-71 22964035
2. A systematic review of treatment guidelines for metastatic colorectal cancer. Edwards MS, Chadda SD, Zhao Z, Barber BL, Sykes DP, Colorectal Dis 2012 14 suppl 2 31 e47 21848897
3. Colorectal cancer: a multipathway disease. Jass JR, Crit Rev Oncog 2006 12 suppl 3-4 273 287 17425506 (Pubitemid 46524134)
4. Drug therapy: EGFR antagonists in cancer treatment. Ciardiello F, Tortora G, NEJM 2008 358 suppl 11 1160 1174 18337605
5. Cetuximab. In the treatment of metastatic colorectal cancer. Reynolds NA, Wagstaff AJ, Drugs 2004 64 suppl 1 109 118 14723561 (Pubitemid 38125631)
6. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E, NEJM 2004 351 suppl 4 337 345 15269313 (Pubitemid 38944402)
7. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR, NEJM 2008 359 suppl 17 1757 1765 18946061
8. Role of Src family kinases in acquired resistance to EGFR therapies in cancer. Boerner JL, Cancer Biol Ther 2009 8 suppl 8 704 706 19417559
9. Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM, Cancer Biol Ther 2009 8 suppl 8 696 703 19276677
10. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. Perkins G, Lièvre A, Ramacci C, Méatchi T, de Reynies A, Emile JF, Boige V, Tomasic G, Bachet JB, Bibeau F, Bouché O, Penault-Llorca F, Merlin JL, Laurent-Puig P, Int J Cancer 2010 127 suppl 6 1321 1331 20049837
11. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A, Cancer Res 2009 69 suppl 5 1851 1857 19223544
12. Nuclear EGFR contributes to acquired resistance to cetuximab. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL, Oncogene 2009 28 suppl 43 3801 3813 19684613
13. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A, Cancer Res 2007 67 suppl 6 2643 2648 17363584 (Pubitemid 46548951)
14. High frequency of mutations of the PIK3CA gene in human cancers. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE, Science 2004 304 suppl 5670 554 15016963 (Pubitemid 38541907)
15. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Perrone F, Lampis A, Orsenigo M, Di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S, Ann Oncol 2009 20 suppl 1 84 90 18669866
16. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM, Cancer Res 2008 68 suppl 6 1953 1961 18339877 (Pubitemid 351416582)
17. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL, Oncol Rep 2009 21 suppl 3 731 735 19212633
18. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F, J Clin Oncol 2009 27 suppl 35 5924 5930 19884556
19. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L, Br J Cancer 2007 97 suppl 8 1139 1145 17940504 (Pubitemid 47587019)
20. A comparison of direct sequencing, pyrosequencing, high resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. Jancik S, Drabek J, Berkovcova J, Xu YZ, Stankova M, Klein J, Kolek V, Skarda J, Tichy T, Grygarkova I, Radzioch D, Hajduch M, J Exp Clin Cancer Res 2012 31 79 10.1186/1756-9966-31-79 22995035
21. Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. Sun L, Zhang Q, Luan H, Zhan Z, Wang C, Sun B, J Exp Clin Cancer Res 2011 17 30
22. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F, Nat Rev Clin Oncol 2009 6 suppl 9 519 527 19636327
23. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. De Roock W, Piessevaux H, De Schutter J, Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL, Peeters M, Humblet Y, Van Cutsem E, Tejpar S, Ann Oncol 2008 19 508 515 17998284 (Pubitemid 351325672)
24. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA 3rd, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ, J Clin Oncol 2007 25 3230 3237 10.1200/JCO.2006.10.5437 17664471 (Pubitemid 47325606)
25. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F, J Clin Oncol 2011 29 suppl 15 2011 2019 21502544
26. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L, Russo A, Perrone G, Tommasino MR, Magnani M, Falcone A, Tonini G, Oncologist 2008 13 suppl 12 1270 1275 19056857
27. K-ras gene mutations in normal colorectal tissues from K-ras mutation-positive colorectal cancer patients. Zhu D, Keohavong P, Finkelstein SD, Swalsky P, Bakker A, Weissfeld J, Srivastava S, Whiteside TL, Cancer Res 1997 57 suppl 12 2485 2492 9192830 (Pubitemid 27255911)
28. Concordance of KRAS/BRAF mutation status in metastatic colorectal cancer before and after anti-EGFR therapy. Gattenlöhner S, Etschmann B, Kunzmann V, Thalheimer A, Hack M, Kleber G, Einsele H, Germer C, Müller-Hermelink HK, J Oncol. 2009 2009 831626 20300583
29. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE, Clin Cancer Res 2010 16 suppl 3 790 799 20103678
30. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Santini D, Vincenzi B, Addeo R, Garufi C, Masi G, Scartozzi M, Mancuso A, Frezza AM, Venditti O, Imperatori M, Schiavon G, Bronte G, Cicero G, Recine F, Maiello E, Cascinu S, Russo A, Falcone A, Tonini G, Ann Oncol 2012 23 2313 2318 10.1093/annonc/mdr623 22396447
31. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Wadlow RC, Hezel AF, Abrams TA, Blaszkowsky LS, Fuchs CS, Kulke MH, Kwak EL, Meyerhardt JA, Ryan DP, Szymonifka J, Wolpin BM, Zhu AX, Clark JW, Oncologist 2012 17 suppl 1 14 22210091
32. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Diaz LA Jr, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B, Nature 2012 486 suppl 7404 537 540 22722843
33. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A, Nature 2012 486 suppl 7404 532 536 22722830
34. ERCC1, KRAS mutation, and oxaliplatin sensitivity in colorectal cancer: old dogs and new tricks. [Abstract]. Orlandi A, Di Salvatore M, Basso M, Bagalà C, Strippoli A, Plastino F, Dadduzio E, Di Lascio S, Quirino M, Cassano A, Astone A, Barone C, J Clin Oncol 2012 30 suppl 4 489
35. KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients. Basso M, Strippoli A, Orlandi A, Martini M, Calegari MA, Schinzari G, Di Salvatore M, Cenci T, Cassano A, Larocca LM, Barone C, Br J Cancer 2013 108 115 120 10.1038/bjc.2012.526 23175150
36. A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and Irinotecan for advanced colorectal cancer (RE-OPEN study): reports of interim analysis [abstract]. Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T, J Clin Oncol 2012 30 suppl 34 580 22253468
37. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Maindrault-Goebel F, Tournigand C, André T, Carola E, Mabro M, Artru P, Louvet C, de Gramont A, Ann Oncol 2004 15 1210 1214 10.1093/annonc/mdh305 15277260 (Pubitemid 39199307)
38. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop and go fashion in advanced colorectal cancer-a GERCOR study. Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, Mineur L, Carola E, Etienne PL, Rivera F, Chirivella I, Perez-Staub N, Louvet C, André T, Tabah-Fisch I, de Gramont A, J Clin Oncol 2006 24 394 400 10.1200/JCO.2005.03.0106 16421419 (Pubitemid 46630458)
39. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study [abstract]. Maindrault-Goebel F, Lledo G, Chibaudel B, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Louvet C, De Gramont A, Proc Am Soc Clin Oncol 2006 24 147s
40. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX 2 Study. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, André T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, Dupuis O, Colin P, Larsen AK, Afchain P, Tournigand C, Louvet C, de Gramont A, J Clin Oncol 2009 27 5727 5733 10.1200/JCO.2009.23.4344 19786657
41. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, Rogers P, Wasan H, Falk S, Gollins S, Hickish T, Bessell EM, Propper D, Kennedy MJ, Kaplan R, Maughan TS, MRC COIN Trial Investigators, Lancet Oncol 2011 12 suppl 7 642 653 21641867
42. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T, J Clin Oncol 2012 30 1755 1762 10.1200/JCO.2011.38.0915 22473155
43. Oral Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): results of the two-arm phase II randomized MRC COIN-b trial. Wasan H, Adams RA, Wilson RH, Pugh C, Fisher D, Madi A, Sizer B, Butler R, Meade A, Maughan TS, Eur J Cancer 2011 47 suppl 1 393
44. Phase III study of first-line XELOX plus Bevacizumab (BEV) for 6 cycles followed by XELOX plus BEV or single-agent (s/a) BEV as maintenance therapy in patients (pts) with metastatic colorectal cancer (mCRC): the MACRO trial (Spanish cooperative group for the treatment of digestive tumors [TTD]) [abstract]. Tabernero J, Aranda E, Gomez A, Massuti B, Sastre J, Abad A, Valladares M, Rivera F, Safont M, Diaz-Rubio E, J Clin Oncol 2010 28 15s
45. Maintenance treatment with capecitabine and Bevacizumab versus observation after induction treatment with chemotherapy and Bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch colorectal cancer group (DCCG) [abstract]. Koopman M, Simkens HJL, Ten Tije AJ, Creemers GJ, Loosveld OJL, de Jongh FE, Erdkamp F, Erjavec Z, van der Torren AME, Van der Hoeven JJM, Nieboer P, Braun JJ, Jansen RL, Haasjes JG, Cats A, Wals JJ, Mol L, Dalesio O, van Tinteren H, Punt CJA, J Clin Oncol in press
46. Enhancement of radiation response with bevacizumab. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM, J Exp Clin Cancer Res 2012 31 37 10.1186/1756-9966-31-37 22538017
47. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S, ML18147 Study Investigators, Lancet Oncol 2013 14 suppl 1 29 37 23168366
48. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M, J Clin Oncol 2008 26 suppl 33 5326 5334 18854571
49. Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP) [abstract]. Cohn AL, Bekaii-Saab T, Bendell JC, Hurwitz H, Kozloff M, Roach N, Tezcan H, Feng S, Sing A, Grothey A, on behalf of the ARIES Study Investigators, J Clin Oncol 2010 28 15s
50. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. Mancuso MR, Davis R, Norberg SM, J Clin Invest 2006 116 suppl 10 2610 2621 17016557 (Pubitemid 44511625)